TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism.
TMAO
TML
liquid chromatography–mass spectrometry
trimethylamine N-oxide
venous thromboembolism
γBB
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
04 Mar 2022
04 Mar 2022
Historique:
received:
28
01
2022
revised:
23
02
2022
accepted:
03
03
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
The present work evaluates the association between circulating concentrations of Trimethylamine-N-oxide (TMAO), gamma butyrobetaine (γBB), and trimetyllisine (TML) in controls and patients with venous thromboembolism (VTE) with coagulation parameters. The study involved 54 VTE patients and 57 controls. Platelet function, platelet hyperreactivity, platelet adhesiveness, thrombosis-associated parameters, and thrombin generation parameters were studied. Plasma TMAO, γBB, and TML determination was performed using an ultra-high-performance liquid chromatography system coupled with mass spectrometry. No differences were found for TMAO, γBB, or TML concentrations between controls and VTE patients. In thrombin generation tests, TMAO, γBB, and TML showed a positive correlation with lag time and time to peak. TMAO, γBB, and TML negatively correlated with peak height. No significant differences were observed regarding TMAO, γBB, and TML concentrations between the two blood withdrawals, nor when the control and VTE patients were analyzed separately. No correlation was observed between these gut metabolites and platelet function parameters. No differences were found regarding TMAO, γBB, and TML concentrations between the control and VTE groups. Some correlations were found; however, they were mild or went in the opposite direction of what would be expected if TMAO and its derivatives were related to VTE risk.
Sections du résumé
BACKGROUND
BACKGROUND
The present work evaluates the association between circulating concentrations of Trimethylamine-N-oxide (TMAO), gamma butyrobetaine (γBB), and trimetyllisine (TML) in controls and patients with venous thromboembolism (VTE) with coagulation parameters.
METHODS
METHODS
The study involved 54 VTE patients and 57 controls. Platelet function, platelet hyperreactivity, platelet adhesiveness, thrombosis-associated parameters, and thrombin generation parameters were studied. Plasma TMAO, γBB, and TML determination was performed using an ultra-high-performance liquid chromatography system coupled with mass spectrometry.
RESULTS
RESULTS
No differences were found for TMAO, γBB, or TML concentrations between controls and VTE patients. In thrombin generation tests, TMAO, γBB, and TML showed a positive correlation with lag time and time to peak. TMAO, γBB, and TML negatively correlated with peak height. No significant differences were observed regarding TMAO, γBB, and TML concentrations between the two blood withdrawals, nor when the control and VTE patients were analyzed separately. No correlation was observed between these gut metabolites and platelet function parameters.
CONCLUSIONS
CONCLUSIONS
No differences were found regarding TMAO, γBB, and TML concentrations between the control and VTE groups. Some correlations were found; however, they were mild or went in the opposite direction of what would be expected if TMAO and its derivatives were related to VTE risk.
Identifiants
pubmed: 35268516
pii: jcm11051425
doi: 10.3390/jcm11051425
pmc: PMC8911412
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : ISCIII
ID : PI18/00164; PI21/00140; PI12/00612; PI15/00269; PI18/00434; PI19/00136
Références
Ann Clin Biochem. 2015 May;52(Pt 3):352-60
pubmed: 25013088
Thromb Res. 2019 Feb;174:40-47
pubmed: 30553164
Biomedicines. 2021 Sep 27;9(10):
pubmed: 34680453
Am J Med Sci. 2019 Dec;358(6):422-428
pubmed: 31666184
Thromb Res. 2019 May;177:110-116
pubmed: 30875490
J Thromb Haemost. 2019 Jan;17(1):3-5
pubmed: 30548165
Atherosclerosis. 2016 Apr;247:64-9
pubmed: 26868510
Anal Biochem. 2014 Jun 15;455:35-40
pubmed: 24704102
Annu Rev Nutr. 2017 Aug 21;37:157-181
pubmed: 28715991
Sci Rep. 2019 Aug 12;9(1):11647
pubmed: 31406181
Cell. 2016 Mar 24;165(1):111-124
pubmed: 26972052
Circulation. 2017 Apr 25;135(17):1671-1673
pubmed: 28438808
Eur Heart J. 2014 Apr;35(14):904-10
pubmed: 24497336
Circ Res. 2018 Oct 26;123(10):1164-1176
pubmed: 30359185
Circ Res. 2020 Feb 28;126(5):660-662
pubmed: 31958034
Thromb Res. 2018 Sep;169:57-63
pubmed: 30015229
J Thromb Haemost. 2018 Sep;16(9):1857-1872
pubmed: 29981269
BMC Infect Dis. 2017 Jun 23;17(1):445
pubmed: 28645263
J Inflamm Res. 2020 Jul 30;13:387-400
pubmed: 32801832
Blood Coagul Fibrinolysis. 2021 Mar 1;32(2):122-131
pubmed: 33337623
Nature. 2011 Apr 7;472(7341):57-63
pubmed: 21475195
Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1045-1054
pubmed: 31070450
Clin Chem Lab Med. 2017 Feb 1;55(2):261-268
pubmed: 27447240
Nat Med. 2018 Sep;24(9):1407-1417
pubmed: 30082863
N Engl J Med. 2013 Apr 25;368(17):1575-84
pubmed: 23614584
J Am Heart Assoc. 2021 Sep 7;10(17):e020646
pubmed: 34398665